|
EP2373300A1
|
|
Transdermal systems containing multilayer adhesive matrices to modify drug delivery
|
|
NZ588695A
|
|
Extended release forumulation containing a wax and ciprofloxacin
|
|
WO2010096068A1
|
|
Controlled release budesonide minitablets
|
|
WO2010096067A1
|
|
Controlled release budesonide minitablets
|
|
AU2008211318A1
|
|
Extended-release dosage form
|
|
CA2693166A1
|
|
Drug formulations having inert sealed cores
|
|
WO2009014532A1
|
|
Stabilized tolterodine tartrate formulations
|
|
US2005202079A1
|
|
Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
|
|
AU2003288977A8
|
|
Transdermal delivery of fentanyl
|
|
WO03041699A1
|
|
Storage stable thyroxine active drug formulations and methods for their production
|
|
US6645526B2
|
|
Storage stable thyroxine active drug formulations and methods for their production
|
|
WO0119348A1
|
|
Stabilization of enalapril maleate with maleic acid
|
|
US6274168B1
|
|
Phenytoin sodium pharmaceutical compositions
|
|
US6071952A
|
|
Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
|
|
CA1220423A
|
|
Pharmaceutical combination composition and associated method
|
|
US4526777A
|
|
Pharmaceutical combination composition and associated method
|
|
US4547498A
|
|
Pharmaceutical combination composition and associated method
|
|
EP0207405A2
|
|
Method for making pharmaceutical combination composition in granularly heterogenous solid unit dosage form with enhanced bioavailability
|
|
US4444769A
|
|
Antihypertensive diuretic combination composition and associated method
|
